Fulcrum Therapeutics
FULC
117 hedge funds and large institutions have $148M invested in Fulcrum Therapeutics in 2025 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 44 reducing their positions, and 19 closing their positions.
270% more call options, than puts
Call options by funds: $148K | Put options by funds: $40K
0.74% less ownership
Funds ownership: 95.9% → 95.16% (-0.74%)
2% less funds holding
Funds holding: 119 → 117 (-2)
11% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 19
30% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 44
39% less capital invested
Capital invested by funds: $243M → $148M (-$95M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$6.35M |
| 2 |
EAM
Exome Asset Management
New York
|
+$1.49M |
| 3 |
Renaissance Technologies
New York
|
+$1.47M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.13M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.58M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.88M |
| 3 |
BlackRock
New York
|
-$1.69M |
| 4 |
PA
Perceptive Advisors
New York
|
-$1.12M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$809K |
FULC Hedge Fund Activity: Q1 2025 in Review
117 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q1 2025, worth a combined $148M — down 39% from $243M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of FULC and 17 opened new positions — a net loss of 2 holders — while 44 trimmed existing stakes and 31 added.
The largest buyer was Suvretta Capital Management, adding an estimated $6.35M. The largest seller was Morgan Stanley, cutting an estimated $4.58M.
- 117 institutional investors held Fulcrum Therapeutics (FULC) as of Q1 2025, down from 119 in Q4 2024.
- Funds reported $148M of Fulcrum Therapeutics stock for Q1 2025, down 39% quarter-over-quarter.
- 17 funds opened new Fulcrum Therapeutics positions in Q1 2025 and 19 closed out, a net change of -2 holders.
- The largest Fulcrum Therapeutics buyer in Q1 2025 was Suvretta Capital Management, an estimated $6.35M added.
- The largest Fulcrum Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $4.58M sold.
Based on aggregated 13F filings for Q1 2025.